- Schanzer JM et al. New monospecific tetravalent antibody comprising monospecific bivalent parent antibody, two peptidic-linkers, and two monospecific monovalent single chain antibodies, useful to treat e.g. HIV, rheumatoid arthritis and allograft rejection. Hoffmann La Roche & Co AG: WO 2010028798/97 A1
- Schanzer JM et al. New bispecific tetravalent anti-C-C chemokine receptor type 5 (anti-CCR5) antibody comprises monospecific bivalent anti-CCR5 parent antibody and monospecific monovalent single chain antibodies, useful for treating, e.g. immunosuppression and HIV. Hoffmann La Roche & Co AG: WO 2010028796/95 A1
- Schanzer JM et al. New bispecific antibody specifically binds to human vascular endothelial growth factor and human angiopoietin-2, useful as a pharmaceutical composition or for manufacturing a medicament for treating cancer or vascular diseases in a patient. Hoffmann La Roche & Co AG: US 20100111967 A1
- Schanzer JM et al. New multispecific antibody comprising full length antibody binding to first antigen and containing two heavy and two light chains and a single chain fragment antigen-binding fragment binding to further antigen, useful for treating cancer. Roche Glycart AG: WO 2010112193 A1
- Schanzer JM et al. New bispecific antibody capable of binding specifically with human v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 and human c-Met (proto oncogene) useful for treating cancer in subjects. Roche Glycart AG: US 20100254988 A1
- Schanzer JM et al. New trivalent, bispecific antibody used for treating cancer, comprises antibody capable of binding to antigen, and polypeptide including heavy chain variable and constant domains and light chain variable and constant domains. Roche Glycart AG: US 20100256340 A1
- Schanzer JM et al. New bispecific antibody that specifically binds to human ErbB-3 and human mesenchymal-epithelial transition factor (c-Met), useful in a composition for treating cancer and for manufacturing a medicament for treating cancer. Roche Glycart AG: US 20100256339 A1
- Schanzer JM et al. New tri- or tetra-specific antibody comprising light and heavy chains of full length antibody which binds to first antigen, and modified light and heavy chains of full length antibody which binds to second antigen, used to treat cancer. Hoffmann La Roche & Co AG: WO 2010136172 A1
- Schanzer JM et al. New bispecific antigen binding protein, comprises two light chains and two heavy chains of an antibody, and two additional Fab fragments of an antibody, useful for preparing a pharmaceutical composition for treating proliferative diseases. Hoffmann La Roche & Co AG: US 20100316645 A1
- Schanzer JM et al. New bispecific/tetravalent antigen binding protein with modified heavy chains of antibodies binding to antigens, where antibody constant heavy chain domain of second antibody is replaced by light chain constant domain, used to treat cancers. Hoffmann La Roche & Co AG: WO 2010145793 A1
- Schanzer JM et al. New bispecific antibody comprises heavy and light chain of two full length antibodies that specifically binds to two antigens respectively, where N-terminus of heavy chain is connected to C-terminus of light chain via peptide linker. Roche Glycart AG: WO 2011117330 A1
- Schanzer JM et al. New bispecific antibody comprising full length antibody binding to antigen, and fragment variable binding to second antigen having heavy/light chain variable domains connected via disulfide bridge, used to treat e.g. cancer. Hoffmann La Roche & Co AG: WO 2012025530 A1
- Schanzer JM et al. New activatable bispecific antibody, useful for treating cancer and inflammation. Roche Glycart AG: WO 2012025525 A1
- Schanzer JM et al. New bispecific antibody comprising a first antigen-binding site that binds to human epidermal growth factor receptor and a second antigen-binding site that binds to human insulin-like growth factor-1 receptor, useful to treat cancer. Roche Glycart AG: WO 2013041462 A1
- Schanzer JM et al. New multispecific antigen binding protein comprising monovalent antigen binding protein and antigen binding peptide specifically binds to antigen, useful for treating cancer e.g. lymphomas or an inflammatory disease. Hoffmann La Roche & Co AG: WO 2013164325 A1
- Schanzer JM et al. New bispecific antibody useful in e.g. pharmaceutical composition for treating cancer, binds to human epidermal growth factor receptor 2 (HER2) containing first antigen binding site specific for extracellular domain II of HER2. Hoffmann La Roche & Co AG: WO 2015091738 A1
